Unlike traditional life science accelerators, Gateway Labs by Lilly has redefined the model by giving participating companies direct access to Lilly scientists, researchers, and executives, as well as exposure to Lilly’s scientific and functional expertise. Companies located at Gateway Labs have the opportunity to collaborate with Lilly and each other on research of mutual interest, participate in shared learning and scientific symposia with Lilly experts and partners, and have the potential for financial investment directly from Lilly, venture capital funds, or both.
Participating companies have raised more than $1B in capital, with Lilly often participating as an investor, supporting the development of more than 20 therapeutics and platforms. One drug candidate from a participating company has already entered Lilly’s pipeline, with more pipeline entries expected in the future.
Learn more about Lilly's approach to partnering.
Lilly has been supporting early phase external innovation for decades, and Gateway Labs is a vibrant and tangible example of this commitment.
Julie Gilmore, Ph.D.Global Head, Gateway Labs by Lilly
